53 results on '"Lutz Gürtler"'
Search Results
2. Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice
- Author
-
Giovanni Di Minno, Mariana Canaro, James W. Ironside, David Navarro, Carlo Federico Perno, Andreas Tiede, and Lutz Gürtler
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2013
- Full Text
- View/download PDF
3. Too Early to Abandon Convalescent Plasma for Supportive Treatment of COVID-19
- Author
-
Rainer Seitz, Lutz Gürtler, Ute Vahlensieck, Anneliese Hilger, and Wolfgang Schramm
- Subjects
Immunology and Allergy ,Hematology - Abstract
The authors of a systematic review and meta-analysis conclude that the benefit of convalescent plasma (CP) in the treatment of COVID-19 is limited. Among other systematic reviews, only one found an indication of benefit of CP. However, a meta-analysis needs a focused and meaningful clinical question and should include studies which are designed to test a reasonable hypothesis. Clinical trials to support the licensing of medicines should aim to define as exactly as possible the investigational drug and target disease. In the case of COVID-19, trial details (e.g., duration, stage and severity of disease, and antibody content and dose of CP) are quite heterogeneous. The so far available evidence suggests that the hypothesis should be sharpened as to treat COVID -19 patients at risk for developing severe disease as early enough with a sufficiently high dose of specific antibodies. It has been demonstrated that such an approach is feasible, and the lack of an independent reproduction by further trials with a really comparable design can probably not be compensated by compiling all available, heterogenous trials, even with the best methodology of a systematic review and meta-analysis. Though the COVID-19 pandemic appears to be fading, we should not neglect the search for effective prevention and treatments, given the still high death toll of COVID-19. Monoclonal antibodies were found effective in the early phase of the pandemic; however, due to new variants of SARS-COV2 undermining their efficacy they are no longer recommended by the current NIH guidelines. CP can provide a spectrum of polyclonal antibodies in close timely and regional connection to the particular prevalent virus variant. It would be extremely valuable to obtain a solid scientific foundation for the principle of target specific and temporarily adapted passive immunization, which could be a fast and flexible instrument also in future outbreaks of novel pathogens.
- Published
- 2023
4. 'Thromboinflammation in COVID-19: can α2-macroglobulin help to control the fire?': Comment from Seitz et al
- Author
-
Rainer Seitz, Lutz Gürtler, and Wolfgang Schramm
- Subjects
Hematology - Published
- 2023
5. Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular application of the vaccine?
- Author
-
Lutz Gürtler, Wolfgang Schramm, and Rainer Seitz
- Subjects
Venous thrombosis ,COVID-19 ,PF4 antibody ,Adenovirus vector ,Thrombocytopenia ,SARS-CoV-2 vaccination ,Microbiology (medical) ,2019-20 coronavirus outbreak ,COVID-19 Vaccines ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Viral vector ,medicine ,Humans ,Venous Thrombosis ,Vaccines ,SARS-CoV-2 ,business.industry ,Vaccination ,Thrombosis ,General Medicine ,medicine.disease ,Virology ,Infectious Diseases ,Commentary ,business - Published
- 2021
6. Thromboinflammation in COVID‐19: Can α2‐macroglobulin help to control the fire?
- Author
-
Wolfgang Schramm, Lutz Gürtler, and Rainer Seitz
- Subjects
Proteases ,Chemistry ,Elastase ,Inflammation ,Hematology ,Neutrophil extracellular traps ,030204 cardiovascular system & hematology ,Cell biology ,Macroglobulin ,03 medical and health sciences ,0302 clinical medicine ,Thrombin ,Extracellular ,medicine ,Platelet ,medicine.symptom ,neutrophil ,COVID-19 ,α2-macroglobulin ,extracellular traps ,endothelial cells ,thromboinflammation ,medicine.drug - Abstract
The complex COVID-19-associated coagulopathy appears to impair prognosis. Recently, we presented the hypothesis that children are to some extent protected by higher α2-macroglobulin (α2-M) levels from severe COVID-19. In addition to endothelial cells, thrombin, and platelets, neutrophil granulocytes also appear to play an important role. Neutrophils extrude extracellular nets, which are histone- and protease-coated web-like DNA structures; activate coagulation and platelets; and release radicals and proteases such as elastase. The unique phylogenetically ancient and “versatile” inhibitor α2-M contributes particularly during childhood to the antithrombin activity of plasma, binds a broad spectrum of proteases, and interacts with other mediators of inflammation such as cytokines. It is suggested that the scope of basic research and clinical studies would include the potential role of α2-M in COVID-19.
- Published
- 2021
7. COVID‐19‐associated coagulopathy—Hypothesis: Are children protected due to enhanced thrombin inhibition by higher α2‐Macroglobulin macroglobulin (α2‐M)?
- Author
-
Rainer Seitz, Wolfgang Schramm, and Lutz Gürtler
- Subjects
Poor prognosis ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Hematology ,030204 cardiovascular system & hematology ,medicine.disease ,Macroglobulin ,03 medical and health sciences ,0302 clinical medicine ,Thrombin ,Immunology ,Coagulopathy ,medicine ,business ,α 2 macroglobulin ,medicine.drug - Abstract
We are overwhelmed by scientific publications on clinical observations, virology and epidemiology of SARS-CoV-2 infections. There is a growing body of evidence that hypercoagulability complicates COVID-19, probably contributing to poor prognosis.
- Published
- 2020
8. Convalescent plasma for administration of passive antibodies against viral agents
- Author
-
Louis M. Aledort, Giovanni Di Minno, Pier Mannuccio Mannucci, James W. Ironside, Lutz Gürtler, and Carlo Federico Perno
- Subjects
2019-20 coronavirus outbreak ,Convalescent plasma ,Coronavirus disease 2019 (COVID-19) ,biology ,business.industry ,SARS-CoV-2 ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Immunization, Passive ,COVID-19 ,Hematology ,Virology ,Plasma ,biology.protein ,Medicine ,Humans ,Antibody ,business ,Coronavirus Infections ,COVID-19 Serotherapy - Published
- 2020
9. Thromboinflammation in COVID-19: Can α
- Author
-
Rainer, Seitz, Lutz, Gürtler, and Wolfgang, Schramm
- Subjects
Inflammation ,SARS-CoV-2 ,Forum ,COVID-19 ,Endothelial Cells ,neutrophil ,Thrombosis ,Extracellular Traps ,COVID‐19 ,Host-Pathogen Interactions ,thromboinflammation ,Animals ,Humans ,alpha-Macroglobulins ,α2‐macroglobulin ,Inflammation Mediators ,Blood Coagulation - Abstract
The complex COVID‐19‐associated coagulopathy appears to impair prognosis. Recently, we presented the hypothesis that children are to some extent protected by higher α2‐macroglobulin (α2‐M) levels from severe COVID‐19. In addition to endothelial cells, thrombin, and platelets, neutrophil granulocytes also appear to play an important role. Neutrophils extrude extracellular nets, which are histone‐ and protease‐coated web‐like DNA structures; activate coagulation and platelets; and release radicals and proteases such as elastase. The unique phylogenetically ancient and “versatile” inhibitor α2‐M contributes particularly during childhood to the antithrombin activity of plasma, binds a broad spectrum of proteases, and interacts with other mediators of inflammation such as cytokines. It is suggested that the scope of basic research and clinical studies would include the potential role of α2‐M in COVID‐19.
- Published
- 2020
10. HIV transmission by human bite: a case report and review of the literature-implications for post-exposure prophylaxis
- Author
-
Christoph Ruwwe-Glösenkamp, Christian Hoffmann, Dirk Schürmann, Miriam Stegemann, and Lutz Gürtler
- Subjects
0301 basic medicine ,Microbiology (medical) ,Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Human immunodeficiency virus (HIV) ,HIV Infections ,Case Report ,medicine.disease_cause ,Post-exposure prophylaxis ,Route of transmission ,Plasma viral load ,03 medical and health sciences ,0302 clinical medicine ,Bites, Human ,Risk Factors ,Internal medicine ,Germany ,parasitic diseases ,medicine ,Humans ,Human bite ,030212 general & internal medicine ,Risk factor ,Hiv transmission ,business.industry ,Transmission (medicine) ,Human immunodeficiency virus ,virus diseases ,General Medicine ,Berlin ,HIV transmission ,030104 developmental biology ,Infectious Diseases ,business ,600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit - Abstract
We report a case of a probable HIV-1 transmission by human bite. The analyzed data from ten previously reported suspected or allegedly confirmed HIV transmissions revealed a deep bleeding bite wound as the primary risk factor. A high HIV plasma viral load and bleeding oral lesions are present most of the time during HIV transmission by bite. HIV post-exposure prophylaxis (PEP) should be recommended in case of a bleeding wound resulting from a bite of an HIV-infected person. PEP was missed in this presented case.
- Published
- 2020
11. Severe underquantification of HIV-1 group O isolates by major commercial PCR-based assays
- Author
-
Ina Ambiel, Mark Wasner, Robert Ehret, Lutz Gürtler, Jean-Christophe Plantier, Lena Stegmann, Albert Heim, Volker Daniel, Annemarie Berger, Josef Eberle, Christoph Sarrazin, Marhild Kortenbusch, Kai Hourfar, Annette Haberl, Martin Stürmer, Maximilian Muenchhoff, and Oliver T. Keppler
- Subjects
0301 basic medicine ,Microbiology (medical) ,Serial dilution ,030106 microbiology ,Pcr assay ,Human immunodeficiency virus (HIV) ,HIV Infections ,Biology ,medicine.disease_cause ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,030212 general & internal medicine ,Genetic diversity ,virus diseases ,Reproducibility of Results ,General Medicine ,Viral Load ,Virology ,Therapeutic monitoring ,Infectious Diseases ,Nucleic acid ,HIV-1 ,RNA, Viral ,Viral load ,Nucleic Acid Amplification Techniques ,Nucleic acid detection - Abstract
HIV-1 diversity poses major challenges to viral load assays because genetic polymorphisms can impede nucleic acid detection. In addition to the on-going viral diversification within the HIV-1 group M pandemic, HIV-1 genetic diversity is further increased by non-group M infections, such as HIV-1 groups O (HIV-1-O), N and P. We here conducted a systematic evaluation of commercially available PCR assays to detect HIV-1-O isolates. We collected 25 primary HIV-1-O isolates covering all genetic clusters within HIV-1-O. Subsequently, this panel of isolates was tested on eight commercially available quantitative and five qualitative HIV-1 PCR-based assays in serial dilutions. Sequence analyses were performed for severe cases of underquantification or lack of detection. We observed differences between the assays in quantification that depended on the HIV-1-O isolate's subgroup. All three tested HIV-1-O subgroup IV isolates were underquantified by the Roche CAP/CTM >800-fold compared to the Abbott RealTime assay. In contrast, the latter assay underquantified several subgroup I isolates >200-fold. Notably, the Xpert HIV-1 Viral Load test from Cepheid failed to detect two of the HIV-1-O isolates, whereas the Roche Cobas 8800 assay readily detected all isolates. Comparative sequence analyses identified polymorphisms in the HIV-1-O long-terminal repeat and integrase genes that likely underlie inadequate nucleic acid amplification. Potential viral load underquantification should be considered in therapeutic monitoring of HIV-1-O-infected patients. Pre-clinical assessments of HIV-1 diagnostic assays could be harmonized by establishing improved and internationally standardized panels of HIV-1 isolates that cover the dynamic diversity of circulating HIV-1 strains.
- Published
- 2019
12. Nachweis einer Infektion mit Humanem Immundefizienzvirus (HIV): Serologisches Screening mit nachfolgender Bestätigungsdiagnostik durch Antikörper-basierte Testsysteme und/oder durch HIV-Nukleinsäure-Nachweis
- Author
-
Lutz Gürtler
- Subjects
Public Health, Environmental and Occupational Health - Published
- 2015
13. Hepatitis E Virus
- Author
-
Hannelore Willkommen, Margarethe Heiden, Ursula Bauerfeind, Georg Pauli, Schottstedt, Sally A. Baylis, Uwe Schlenkrich, Gärtner B, Rainer Seitz, Aepfelbacher M, Ruth Offergeld, Reinhard Burger, Lutz Gürtler, Martin Hildebrandt, Johanna Strobel, Johannes Blümel, Albrecht Gröner, and Bernd Jansen
- Subjects
business.industry ,Zoonosis ,Hematology ,medicine.disease ,medicine.disease_cause ,Data science ,Virology ,Text mining ,Hepatitis E virus ,Chronic hepatitis ,Clinical Information ,medicine ,Immunology and Allergy ,business - Published
- 2015
14. Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?
- Author
-
Hermann Eichler, Andreas Tiede, James W. Ironside, Giovanni Di Minno, Mariana Canaro, David Navarro, Carlo Federico Perno, Lutz Gürtler, Di Minno, Giovanni, Navarro, David, Perno, Carlo Federico, Canaro, Mariana, Gürtler, Lutz, Ironside, James W., Eichler, Hermann, and Tiede, Andreas
- Subjects
Infection risk ,Blood transfusion ,medicine.medical_treatment ,Review Article ,030204 cardiovascular system & hematology ,Hemorrhagic disorder ,Inactivation ,0302 clinical medicine ,Risk Factors ,Blood product ,Medicine ,Pathogen ,Bleeding disorder ,Hematology ,Viru ,General Medicine ,Blood Coagulation Disorders ,Virus ,Hemorrhagic Disorder ,Blood ,Blood-Borne Pathogens ,Human ,medicine.medical_specialty ,Sepsi ,Blood Safety ,Hemorrhagic Disorders ,Risk Assessment ,Sepsis ,03 medical and health sciences ,Internal medicine ,Journal Article ,Humans ,Blood Transfusion ,Blood Coagulation Disorder ,business.industry ,Risk Factor ,Clotting ,medicine.disease ,Blood-Borne Pathogen ,Residual risk ,Disinfection ,Patient information ,Immunology ,business ,Removal ,030215 immunology - Abstract
Patients with blood disorders (including leukaemia, platelet function disorders and coagulation factor deficiencies) or acute bleeding receive blood-derived products, such as red blood cells, platelet concentrates and plasma-derived products. Although the risk of pathogen contamination of blood products has fallen considerably over the past three decades, contamination is still a topic of concern. In order to counsel patients and obtain informed consent before transfusion, physicians are required to keep up to date with current knowledge on residual risk of pathogen transmission and methods of pathogen removal/inactivation. Here, we describe pathogens relevant to transfusion of blood products and discuss contemporary pathogen removal/inactivation procedures, as well as the potential risks associated with these products: the risk of contamination by infectious agents varies according to blood product/region, and there is a fine line between adequate inactivation and functional impairment of the product. The cost implications of implementing pathogen inactivation technology are also considered.
- Published
- 2017
15. Arbonematodes – Nematode Infections Transmissible by Arthropods
- Author
-
Ursula Bauerfeind, Hannelore Willkommen, Johanna Strobel, Ruth Offergeld, Uwe Schlenkrich, Georg Pauli, Martin Hildebrandt, Johannes Blümel, Lutz Gürtler, Albrecht Gröner, Thomas Montag-Lessing, Christian Drosten, Reinhard Burger, Volkmar Schottstedt, Margarethe Heiden, Bernd Jansen, and Rainer Seitz
- Subjects
biology ,Ehrlichia ,Culex ,Hematology ,biology.organism_classification ,medicine.disease_cause ,Virology ,Wuchereria bancrofti ,medicine ,Trypanosoma ,Immunology and Allergy ,Anaplasma ,Phlebotomus ,Simulium ,Loa loa - Abstract
Some alphaviruses and flaviviruses, such as the transfusion-relevant Chikungunya and West-Nile virus, are transmitted by mosquitoes. Such viruses are called arboviruses. Bacteria typically transmitted by ticks include Coxiella burnetii [1], Borrelia, Ehrlichia, and Anaplasma. These are referred to as arbobacteria [2]. Protozoae include plasmodia which are transmitted via mosquitoes, leishmania transmitted via sand flies (Phlebotomus), and for example trypanosoma transmitted via kissing bugs (Triatoma). The latter are grouped under the name arboprotozoa [3]. The following nematodes are transmitted by arthropods as vectors to humans: microfilaria of Wuchereria bancrofti via mosquitoes (Culex), Onchocera (Onchocera volvulus in Africa, O. caecutiens in South America) via black fly (Simulium) and Loa loa (African eye worm) via horse flies (Tabanidae) – therefore these agents are here grouped under the name arbonematodes.
- Published
- 2013
16. Potent in vitro antiviral activity of Cistus incanus extract against HIV and Filoviruses targets viral envelope proteins
- Author
-
Ruth Brack-Werner, Stephanie Rebensburg, Martha Schneider, Josef Eberle, Markus Helfer, Michael Schindler, Herwig Koppensteiner, and Lutz Gürtler
- Subjects
0301 basic medicine ,viruses ,030106 microbiology ,Microbial Sensitivity Tests ,Drug resistance ,Biology ,Virus Replication ,Antiviral Agents ,Article ,Virus ,Cell Line ,Marburg virus ,03 medical and health sciences ,Viral Envelope Proteins ,Viral envelope ,Drug Resistance, Viral ,Humans ,Antibody-dependent enhancement ,Cells, Cultured ,Multidisciplinary ,Dose-Response Relationship, Drug ,Plant Extracts ,Cistus ,Polyphenols ,Cistus × incanus ,Filoviridae ,Virology ,In vitro ,030104 developmental biology ,Cell culture ,HIV-1 - Abstract
Novel therapeutic options are urgently needed to improve global treatment of virus infections. Herbal products with confirmed clinical safety features are attractive starting material for the identification of new antiviral activities. Here we demonstrate that Cistus incanus (Ci) herbal products inhibit human immunodeficiency virus (HIV) infections in vitro. Ci extract inhibited clinical HIV-1 and HIV-2 isolates, and, importantly, a virus isolate with multiple drug resistances, confirming broad anti-HIV activity. Antiviral activity was highly selective for virus particles, preventing primary attachment of the virus to the cell surface and viral envelope proteins from binding to heparin. Bioassay-guided fractionation indicated that Ci extract contains numerous antiviral compounds and therefore has favorably low propensity to induce virus resistance. Indeed, no resistant viruses emerged during 24 weeks of continuous propagation of the virus in the presence of Ci extracts. Finally, Ci extracts also inhibited infection by virus particles pseudotyped with Ebola and Marburg virus envelope proteins, indicating that antiviral activity of Ci extract extends to emerging viral pathogens. These results demonstrate that Ci extracts show potent and broad in vitro antiviral activity against viruses that cause life-threatening diseases in humans and are promising sources of agents that target virus particles.
- Published
- 2016
17. The Evolution of Drug Resistance Interpretation Algorithms: ANRS, REGA and Extension of Resistance Analysis to HIV-1 Group O and HIV-2
- Author
-
Josef Eberle and Lutz Gürtler
- Subjects
Genotype ,Hepacivirus ,Human immunodeficiency virus (HIV) ,Microbial Sensitivity Tests ,Drug resistance ,medicine.disease_cause ,Interpretation (model theory) ,Virology ,Drug Resistance, Viral ,medicine ,Humans ,Single amino acid ,Genetics ,Mutation ,biology ,Computational Biology ,biology.organism_classification ,Molecular Typing ,Infectious Diseases ,Virus Diseases ,Data Interpretation, Statistical ,HIV-2 ,HIV-1 ,Algorithm ,Algorithms ,HIV drug resistance - Abstract
Antiretroviral drug resistance is mostly linked to a complex interaction of several amino acids with variable importance or a single amino acid. To facilitate the interpretation of observed mutation patterns, hospital university centers have developed several interpretation systems. All the currently available interpretation algorithms evolved, are being continuously updated and have been improved during the last decade. Some discrepancies are still evident that are partially smoothened by link of the individual programs with other systems. After the interpretation of HIV-1 group M subtype B mutations, a refined algorithm for the other group M subtypes was developed followed by the interpretation of HIV-1 group O and HIV-2 mutations. The process of improvement is ongoing, due to the better understanding and interpretation of single and cluster mutations and the availability of new antiretroviral substances. The knowledge gained from the experience of HIV drug resistance testing has been used to establish the interpretation of HBV polymerase mutations and will be extended for the treatment of HCV infected with protease inhibitors.
- Published
- 2012
18. Confirmation of Putative HIV-1 Group P in Cameroon
- Author
-
Lutz Gürtler, Sushil G. Devare, Lazare Kaptue, Julie Yamaguchi, Dora Mbanya, Charlotte Ngansop, Catherine A. Brennan, Ana Vallari, Florence Makamche, Barbara J. Harris, Nicaise Ndembi, and Vera Holzmayer
- Subjects
Male ,Lineage (genetic) ,Genotype ,Molecular Sequence Data ,Immunology ,Human immunodeficiency virus (HIV) ,HIV Infections ,Biology ,medicine.disease_cause ,Microbiology ,Virus ,Virology ,Prevalence ,medicine ,Humans ,Cameroon ,Hospital patients ,virus diseases ,Sequence Analysis, DNA ,Middle Aged ,Simian immunodeficiency virus ,biology.organism_classification ,Clinical research ,Genetic Diversity and Evolution ,Insect Science ,Lentivirus ,HIV-1 ,Simian Immunodeficiency Virus - Abstract
We report the second human immunodeficiency virus (HIV) belonging to the new HIV type 1 (HIV-1) group P lineage that is closely related to the simian immunodeficiency virus found in gorillas. This virus was identified in an HIV-seropositive male hospital patient in Cameroon, confirming that the group P virus is circulating in humans. Results from screening 1,736 HIV-seropositive specimens collected in Cameroon indicate that HIV-1 group P infections are rare, accounting for only 0.06% of HIV infections. Despite its rarity, group P shows evidence of adaptation to humans.
- Published
- 2011
19. Parvovirus B19 – Revised
- Author
-
Margarethe Heiden, Schottstedt, Uwe Schlenkrich, Thomas Montag-Lessing, Hannelore Willkommen, Martin Hildebrandt, Lutz Gürtler, Johannes Blümel, Albrecht Gröner, Christian Drosten, von König Ch, Bernd Jansen, Johanna Strobel, Rainer Seitz, Reinhard Burger, Ruth Offergeld, and Georg Pauli
- Subjects
biology ,Parvovirus ,business.industry ,Immunology ,Immunology and Allergy ,Medicine ,Hematology ,biology.organism_classification ,business ,Clinical Information · Klinische Information ,Virology - Published
- 2010
20. Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus
- Author
-
Martin Stürmer, Hans Wilhelm Doerr, and Lutz Gürtler
- Subjects
Microbiology (medical) ,Sexually transmitted disease ,Anti-HIV Agents ,Immunology ,HIV Infections ,Review ,medicine.disease_cause ,Virus ,Orthohepadnavirus ,Acquired immunodeficiency syndrome (AIDS) ,HBV ,medicine ,Virus maturation ,Humans ,Immunology and Allergy ,Diagnostics ,Hepatitis B virus ,biology ,HIV ,General Medicine ,Hepatitis B ,biology.organism_classification ,medicine.disease ,Hepatitis C ,Virology ,Drug Design ,HCV ,Therapy ,Viral load - Abstract
The human immunodeficiency virus (HIV) had spread unrecognized in the human population as sexually transmitted disease and was finally identified by its disease AIDS in 1981. Even after the isolation of the causative agent in 1983, the burden and death rate of AIDS accelerated worldwide especially in young people despite the confection of new drugs capable to inhibit virus replication since 1997. However, at least in industrialised countries, this trend could be reversed by the introduction of combination therapy strategies. The design of new drugs is on going; besides the inhibition of the three enzymes of HIV for replication and maturation (reverse transcriptase, integrase and protease), further drugs inhibits fusion of viral and cellular membranes and virus maturation. On the other hand, viral diagnostics had been considerably improved since the emergence of HIV. There was a need to identify infected people correctly, to follow up the course of immune reconstitution of patients by measuring viral load and CD4 cells, and to analyse drug escape mutations leading to drug resistance. Both the development of drugs and the refined diagnostics have been transferred to the treatment of patients infected with hepatitis B virus (HBV) and hepatitis C virus (HCV). This progress is not completed; there are beneficial aspects in the response of the scientific community to the HIV burden for the management of other viral diseases. These aspects are described in this contribution. Further aspects as handling a stigmatising disease, education of self-responsiveness within sexual relationships, and ways for confection of a protective vaccine are not covered.
- Published
- 2009
21. Nukleinsäure-Amplifikationstests für HIV, HBV und HCV bei Gewebespendern: Sinnvoll oder überflüssig?
- Author
-
Axel Pruß, Ernst-Markus Quenzel, Lutz Gürtler, G. Caspari, Micha Nübling, Ulrich Kalus, Wolfram H. Gerlich, Detlev H. Krüger, and Johannes Blümel
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,Human immunodeficiency virus (HIV) ,Immunology and Allergy ,Medicine ,Hematology ,business ,medicine.disease_cause - Abstract
Mit der Umsetzung der EU-Richtlinien 2004/23/EG und 2006/17/EG im Gewebegesetz sowie den begleitenden Verordnungen (Arzneimittel- und Wirkstoffherstellungsverordnung, Transplantationsgesetz-Gewebeverordnung) wurden die grundlegenden Anforderungen an die Virussicherheit der Gewebespenden allgemein definiert. Wahrend infektionsserologische Testungen (Anti-HIV 1/2, Anti-HCV, Hepatitis-B-Oberflachenantigen, Anti-Hepatitis-B-Core-Antigen, Treponema-pallidum-Hamagglutinationsassay) vorgeschrieben sind, wird der Nukleinsaure-Nachweis fur HIV, HBV und HCV nicht explizit gefordert. Anhand in der Literatur berichteter Virusubertragungen, gewebespezifischer Besonderheiten sowie Herstellungs- und gegebenenfalls Inaktivierungsverfahren wird eine Bewertung des Stellenwertes des HIV/HCV/HBV-Nachweises mittels Nukleinsaure-Amplifikationstechniken (NAT) bei Spendern unterschiedlicher Gewebe vorgenommen und mit den Erfahrungen des Blutspendewesens verglichen. Muskuloskelettale Gewebe besitzen infolge des zumeist hohen Blutgehalts der Gewebe, des umfangreichen Entnahmespektrums, der bisher beschriebenen Ubertragungen, der unterschiedlichen Herstellungsverfahren sowie der hohen Spender-Empfanger-Ratio ein signifikantes Risiko, HIV/HCV/HBV zu ubertragen. Daher sollte bei Spendern muskuloskelettaler Gewebe, die keinem effektiven Virusinaktivierungsverfahren unterzogen werden, eine HIV-, HBV- und HCV-NAT-Testung erfolgen. Kardiovaskulares Gewebe hat bei Durchfuhrung der serologischen Testung ein sehr geringes Restrisiko der HIV/HCV/HBV-Ubertragung. Aufgrund der fehlenden Moglichkeit einer effektiven Virusinaktivierung (Erhalt der Gewebemorphologie) und der Spender-Empfanger-Ratio von bis zu 1:10 sollte die HIV-, HCV- und HBV-NAT jedoch als zusatzliche Sicherheitsmasnahme erfolgen. Augenhornhaute besitzen aus physiologisch-morphologischer sowie epidemiologischer Sicht das geringste HIV/HCV/HBV-Ubertragungsrisiko, jedoch sollte die HCV-NAT durchgefuhrt werden. Eine Quarantanelagerung der Gewebe eines Spenders kann bei negativem Ergebnis der HIV/HCV/HBV-NAT grundsatzlich entfallen. Aufgrund der vielfaltigen Synergieeffekte mit der Transfusionsmedizin bietet es sich fur Gewebebanken an, die Testung der infektionsserologischen bzw. molekularbiologischen Laborparameter in Kooperation mit Blutspendediensten durchzufuhren.
- Published
- 2008
22. Arbobacteria – Pathogens Transmittable by Arthropods
- Author
-
Christian Drosten, Georg Pauli, Walter E. Hitzler, Ruth Offergeld, Horst Klamm, Bernd Jansen, Reinhard Burger, Thomas Montag-Lessing, Volkmar Schottstedt, Lutz Gürtler, Wolf-Dieter Ludwig, Margarethe Heiden, Uwe Schlenkrich, Hannelore Willkommen, Johannes Blümel, Albrecht Gröner, and Rainer Seitz
- Subjects
Bartonella ,biology ,Ehrlichia ,Hematology ,bacterial infections and mycoses ,biology.organism_classification ,Coxiella burnetii ,Virology ,Microbiology ,Rickettsia prowazekii ,bacteria ,Immunology and Allergy ,Ehrlichia chaffeensis ,Anaplasma ,Rickettsiales ,Francisella tularensis - Abstract
Anaplasma phagocytophilum, marginatum; Bartonella henselae; Borrelia burgdorferi, afzelii, garinii; Coxiella burnetii; Ehrlichia chaffeensis; Francisella tularensis; Rickettsia prowazekii, akari, rickettsii andYersinia pestis are also known as arbobacteria. Diseases caused by these bacteria are basically zoonoses, i.e. diseases transmittable from animals to humans, and have been known as such for about 100 years (table (table1).1). A part of the individual pathogens have not been described until the past few decades. Based on molecular biology analyses, R. prowazekii, Ehrlichia and Anaplasma are categorised as Rickettsiales, while Bartonella is categorised as alpha-2-proteobacteria, Coxiella, Rickettsia grylli and F. tularensis as gamma proteobacteria, and Y. pestis as enterobacteria [1]. Table 1 Vectors for arbobacteria Most arbobacteria grow predominantly intracellularly. However, Borrelia bacteria grow intracellularly and extracellularly, and Yersinia mainly extracellularly. The above described arbobacteria, when transmitted by ticks, show seasonal occurrence and a partly changed antigen repertoire in vector and mammal. R. prowazekii is transmitted by lice world-wide throughout the year. The major clinical symptoms such infections have in common include fever, exanthema, headache, and lymph node swelling, partly a pronounced erythema at the site of the sting, and encephalitic disorders. Neutropenia and thrombocytopenia can occur later. Treatment: Doxycycline is the treatment of choice against most of these bacteria, followed by chloramphenicol and cephalosporins. Quinolones are ineffective against R. prowazekii. The treatment of choice against Y. pestis and F. tularensis is streptomycin or gentamycin, and in addition doxycycline or ciprofloxacine. C. burnetii has been dealt with separately [2]. Therefore, this pathogen is not included in the present review, neither are rare tropical and/or pure tropical diseases. The oriental flea (Xenopsylla cheopsis) is considered as the most effective transmitter for Y. pestis. More than 30 other flea species are known which can transmit Y. pestis as intermediary hosts, including Pulex irritans (human flea), which can play a role in human-to-human transmission. The human louse can also be a vector for transmission of Y. pestis [3]. The following section provides for each pathogen information on the general state of knowledge, characteristics of the pathogen, infectious disease, epidemiology, methods of detection and occurrence of the pathogen in the donor population. This is followed by information concerning all pathogens on epidemiology, defence situation, treatment and prevention in recipient populations as well as a summary evaluation.
- Published
- 2008
23. Rates of Postoperative Complications among Human Immunodeficiency Virus–Infected Women Who Have Undergone Obstetric and Gynecologic Surgical Procedures
- Author
-
Manfred Stauber, Bernd H. Belohradsky, Olaf Dathe, Daniela Reindell, Thomas Grubert, Lutz Gürtler, and Ralph Kästner
- Subjects
Adult ,Microbiology (medical) ,medicine.medical_specialty ,medicine.medical_treatment ,Obstetric Surgical Procedures ,HIV Infections ,Gynecologic Surgical Procedures ,Postoperative Complications ,Acquired immunodeficiency syndrome (AIDS) ,Risk Factors ,Humans ,Medicine ,Antibiotic prophylaxis ,Risk factor ,Sida ,biology ,business.industry ,Immunity ,Odds ratio ,biology.organism_classification ,medicine.disease ,Curettage ,Surgery ,Women's Health Services ,Infectious Diseases ,Female ,Morbidity ,business ,Complication ,Abdominal surgery - Abstract
Clinical observations indicate that human immunodeficiency virus (HIV)‐positive women experience more postoperative problems than do HIV-negative women. To obtain a better estimate of the individual risk of postoperative morbidity among HIV-infected women, and to determine which procedures pose the greatest risk, we performed a retrospective case-control study in which we assessed the outcomes after 235 obstetric and gynecologic surgical procedures. For purposes of comparison, an HIV-negative control patient was matched for each of the 235 surgical procedures performed, on the basis of the type of procedure and patient age. We found a significantly greater number of postoperative complications among the HIV-positive women. Higher complication rates occurred after abdominal surgery (odds ratio [OR], 3.6; ) and curettage (OR, 7.7; P p .001 ). Among HIV-infected women, the risk of complications was associated with immune status. AntiP p .06 retroviral therapy and standard perioperative antibiotic prophylaxis did not decrease the risk of complications. Indications for performing abdominal surgery and curettage on HIV-infected women should be carefully weighed against the potential risk of postoperative complications.
- Published
- 2002
24. Contents Vol. 35, 2008
- Author
-
Thomas Reinhard, Frank-Peter Nitschke, Christoph Ahlke, Alexandra Mertens, Axel Pruß, Micha Nübling, G. Caspari, Horst Hasskarl, Jan Schroeter, Hermann O. Mayr, Bita Bakhschai, Ulrich Kalus, Jürgen Scherer, Walter Sibrowski, Lutz Gürtler, Ernst-Markus Quenzel, Friedger von Auer, Sven Scheffler, Klaus Cichutek, Dörthe Willkomm, Johannes Blümel, Detlev H. Krüger, Dagmar Schilling-Leiß, Antonia W. Godehardt, Ralf R. Tönjes, Bernd-Dietrich Katthagen, Wolfram H. Gerlich, Philip Maier, Roland Becker, Peter Schlenke, Peter Rieck, and Karin Tapernon
- Subjects
Immunology and Allergy ,Hematology - Published
- 2008
25. HIV-2EU—Supporting Standardized HIV-2 Drug-Resistance Interpretation in Europe: An Update: Table 1
- Author
-
Martin Stürmer, Alejandro Pironti, Ricardo Jorge Camacho, Josef Eberle, Martin Obermeier, Françoise Brun-Vézinet, Charlotte Charpentier, Rolf Kaiser, Jean Ruelle, Lutz Gürtler, and Diane Descamps
- Subjects
Microbiology (medical) ,German ,Infectious Diseases ,business.industry ,language ,Ludwig maximilian university ,Human immunodeficiency virus (HIV) ,medicine ,Library science ,Reference laboratory ,medicine.disease_cause ,business ,language.human_language - Abstract
1IAME, UMR 1137, Univ Paris Diderot, Sorbonne Paris Cite, F-75018 Paris, France 2IAME, UMR 1137, INSERM, F-75018 Paris, France 3AP-HP, Hopital Bichat-Claude Bernard, Laboratoire de Virologie, F-75018 Paris, France 4Clinical and Epidemiological Virology, Rega Institute for Medical Research, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium 5Universite catholique de Louvain, AIDS Reference Laboratory, Brussels, Belgium 6Max von Pettenkofer Institute, Ludwig Maximilian University Munich, Munich, Germany 7Max Planck Institute for Informatics, Saarbrucken, Germany 8Johann Wolfgang Goethe-University Hospital, Institute for Medical Virology, German National Reference Centre for Retroviruses, Frankfurt, Germany 9Institute of Virology, University of Cologne, Germany 10Medizinisches Labor Dr. Berg, Berlin, Germany
- Published
- 2015
26. Briefe an den Herausgeber · Letters to the Editor
- Author
-
U. Finsterer, Markus Rehm, W.K. Roth, G. Lerch, C. Akbulut, M.P. Busch, J. Barbara, U. Bothner, J. Löwer, N. Vogt, Lutz Gürtler, H. Hampl, Michael Georgieff, S.L. Stramer, M. Haller, and H. Brechtelsbauer
- Subjects
business.industry ,Immunology and Allergy ,Medicine ,Physiology ,Hematology ,business ,Classics - Published
- 1998
27. Complement Activation by HIV-1–Infected Cells
- Author
-
Anton Hittmair, Christina Ochsenbauer, Valerie Bosch, Josef R. Patsch, Lutz Gürtler, Manfred P. Dierich, Peter Marschang, and Ute Krüger
- Subjects
Blotting, Western ,Immunology ,Transfection ,Epitope ,Cell Line ,Classical complement pathway ,Virology ,Chlorocebus aethiops ,Animals ,Humans ,Immunology and Allergy ,Fluorescent Antibody Technique, Indirect ,Complement Activation ,Decay-accelerating factor ,biology ,Complement component 2 ,Complement C1q ,virus diseases ,Complement C3 ,Flow Cytometry ,Molecular biology ,HIV Envelope Protein gp41 ,Complement system ,Factor H ,CD4 Antigens ,HIV-1 ,biology.protein ,Alternative complement pathway ,HeLa Cells ,Complement control protein - Abstract
To characterize the mechanisms of complement activation by human immunodeficiency virus type 1 (HIV-1)-infected cells, Cl-4 cells stably expressing the envelope glycoproteins of HIV-1 and the parent African green monkey cell line CV-1 were tested for C1q binding and complement activation. While the parent cell line CV-1 only showed a weak spontaneous activation of the alternative pathway, Cl-4 cells additionally triggered the classical pathway of complement activation independent of anti-HIV antibodies by direct C1q binding. Earlier studies had shown different complement activating potential of cells infected with various HIV isolates. Recombinant soluble CD4-induced shedding of gp120 from the surface of HIV-1-infected cells converted a weak activator isolate (MVP-899) into a strong complement activator. The increase in complement activation was paralleled by the concomitant unmasking of a previously hidden gp41 epitope comprising the major complement-activating domain of gp41 (aa. 601-613). Our results strongly suggest that the transmembrane protein gp41 induces the activation of complement on the surface of infected cells as has been described previously for purified HIV-1 virions. Furthermore, we present evidence that the different potential of HIV isolates to activate the complement system on the cell surface is caused by different degrees of spontaneous gp120 shedding by various HIV isolates.
- Published
- 1997
28. Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice
- Author
-
Andreas Tiede, James W. Ironside, Mariana Canaro, Giovanni Di Minno, Carlo Federico Perno, Lutz Gürtler, David Navarro, DI MINNO, Giovanni, Canaro, M, Ironside, Jw, Navarro, D, Perno, Cf, Tiede, A, and Gürtler, L.
- Subjects
congenital, hereditary, and neonatal diseases and abnormalities ,Pediatrics ,medicine.medical_specialty ,Time Factors ,Long term treatment ,Blood transfusion ,medicine.medical_treatment ,Treatment outcome ,Editorials and Perspectives ,Hemophilia A ,Hemorrhagic Disorders ,Hemorrhagic disorder ,hemic and lymphatic diseases ,Blood-Borne Pathogens ,medicine ,Humans ,Blood Transfusion ,Pathogen ,Clotting factor ,business.industry ,Hematology ,Recombinant Proteins ,Treatment Outcome ,Current practice ,Immunology ,business - Abstract
Hemophilia defines a group of hereditary bleeding disorders: hemophilia A (deficiency of Factor VIII, FVIII), hemophilia B (deficiency of FIX), and para-hemophilia (deficiency of FV). These result from mutations in clotting factor genes. As in the large majority of bleeding disorders ([Table 1][1
- Published
- 2013
29. West nile virus
- Author
-
Georg, Pauli, Ursula, Bauerfeind, Johannes, Blümel, Reinhard, Burger, Christian, Drosten, Albrecht, Gröner, Lutz, Gürtler, Margarethe, Heiden, Martin, Hildebrandt, Bernd, Jansen, Thomas, Montag-Lessing, Ruth, Offergeld, Rainer, Seitz, Uwe, Schlenkrich, Volkmar, Schottstedt, Johanna, Strobel, and Hannelore, Willkommen
- Subjects
Clinical Information - Published
- 2012
30. Arbonematodes - nematode infections transmissible by arthropods: arbeitskreis blut, untergruppe «bewertung blutassoziierter krankheitserreger»*
- Author
-
Lutz, Gürtler, Ursula, Bauerfeind, Johannes, Blümel, Reinhard, Burger, Christian, Drosten, Albrecht, Gröner, Margarethe, Heiden, Martin, Hildebrandt, Bernd, Jansen, Thomas, Montag-Lessing, Ruth, Offergeld, Georg, Pauli, Rainer, Seitz, Uwe, Schlenkrich, Volkmar, Schottstedt, Johanna, Strobel, and Hannelore, Willkommen
- Subjects
Clinical Information - Published
- 2012
31. Comparison of Drug Resistance Scores for Tipranavir in Protease Inhibitor-Naïve Patients Infected with HIV-1 B and Non-B Subtypes ▿
- Author
-
Martin Stürmer, Pierre Lecocq, G Knecht, Hans Wilhelm Doerr, Lutz Gürtler, Peter Gute, Markus Bickel, Christoph Stephan, H. R. Brodt, and Margriet Van Houtte
- Subjects
Genotype ,Anti-HIV Agents ,Pyridines ,medicine.medical_treatment ,Human immunodeficiency virus (HIV) ,HIV Infections ,Drug resistance ,Biology ,medicine.disease_cause ,Antiviral Agents ,Drug Resistance, Viral ,medicine ,HIV Protease Inhibitor ,Humans ,Pharmacology (medical) ,Protease inhibitor (pharmacology) ,Pharmacology ,Sulfonamides ,Protease ,HIV Protease Inhibitors ,Infectious Diseases ,Pyrones ,Immunology ,Cohort ,Mutation ,Tipranavir ,medicine.drug - Abstract
Genotypes of samples from protease inhibitor-naïve patients in Frankfurt's HIV Cohort were analyzed with five tipranavir resistance prediction algorithms. Mean scores were higher in non-B than in B subtypes. The proportion of non-B subtypes increased with increasing scores, except in weighted algorithms. Virtual and in vitro phenotype analyses of samples with increased scores showed no reduced tipranavir susceptibility. Current algorithms appear suboptimal for interpretation of resistance to tipranavir in non-B subtypes; increased scores might reflect algorithm bias rather than “natural resistance.”
- Published
- 2011
32. Mutations in the C-terminal region of the HIV-1 reverse transcriptase and their correlation with drug resistance associated mutations and antiviral treatment
- Author
-
Martin Stürmer, Lutz Gürtler, I Michels, A Müller, L Locher, Gaby Nisius, Schlomo Staszewski, and H-W Doerr
- Subjects
genotypic resistance ,RNase H ,RNase P ,Anti-HIV Agents ,antiretroviral therapy ,Drug Resistance ,lcsh:Medicine ,HIV Infections ,Biology ,medicine.disease_cause ,Virus Replication ,Polymerase Chain Reaction ,Virus ,Zidovudine ,Genotype ,reverse transcriptase ,medicine ,Humans ,Taq Polymerase ,connection domain ,Genetics ,Mutation ,Research ,lcsh:R ,General Medicine ,Virology ,Reverse transcriptase ,HIV Reverse Transcriptase ,polymerase ,Amino Acid Substitution ,Anti-Retroviral Agents ,biology.protein ,HIV-1 ,RNA, Viral ,Primer (molecular biology) ,medicine.drug - Abstract
Objective Replication of HIV-1 after cell entry is essentially dependent on the reverse transcriptase (RT). Antiretroviral drugs impairing the function of the RT currently aim at the polymerase subunit. One reason for failure of antiretroviral treatment is the evolvement of resistance-associated mutations in the viral genome. For RT inhibitors, almost all identified mutations are located within the polymerase; therefore, general genotyping confines to investigate this subunit. Recently several studies have shown that substitutions within the RNase H and the connection domain increase antiviral drug-resistance in vitro, and some of them are present in patient isolates. Aim The aim of the present study was to investigate the prevalence of these substitutions and their association with mutations in the polymerase domain arising during antiretroviral treatment. Materials and methods We performed genotypic analyzes on seventy-four virus isolates derived from treated and untreated patients, followed at the HIV Centre of the Johann Wolfgang Goethe University Hospital (Frankfurt/Main, Germany). We subsequently analysed the different substitutions in the c-terminal region to evaluate whether there were associations with each other, n-terminal substitutions or with antiretroviral treatment. Results We identified several primer grip substitutions, but almost all of them were located in the connection domain. This is consistent with other in-vivo studies, in which especially the primer grip residues located in the RNase H were unvaried. Furthermore, we identified other substitutions in the connection domain and in the RNase H. Especially E399D seemed to be associated with an antiretroviral treatment and N-terminal resistance-delivering mutations. Conclusion Some of the identified substitutions were associated with antiviral treatment and drug resistance-associated mutations. Due to the low prevalence of C-terminal mutations and as only a few of them could be associated with antiviral treatment and N-terminal resistance-delivering mutations, we would not recommend routinely testing of the C-terminal RT region.
- Published
- 2010
33. Orthopox Viruses: Infections in Humans
- Author
-
Johannes Blümel, Albrecht Gröner, Thomas Montag-Lessing, Carl-Heinz Wirsing von König, Uwe Schlenkrich, Christian Drosten, Lutz Gürtler, Hannelore Willkommen, Volkmar Schottstedt, Margarethe Heiden, Johanna Strobel, Georg Pauli, Rainer Seitz, Martin Hildebrandt, Reinhard Burger, Bernd Jansen, and Ruth Offergeld
- Subjects
business.industry ,Immunology and Allergy ,Medicine ,Hematology ,Computational biology ,business ,Bioinformatics ,Clinical Information · Klinische Information - Published
- 2010
34. Human Cytomegalovirus (HCMV) - Revised
- Author
-
Ruth Offergeld, Lutz Gürtler, Volkmar Schottstedt, Uwe Schlenkrich, Martin Hildebrandt, Carl-Heinz Wirsing von König, Hannelore Willkommen, Margarethe Heiden, Bernd Jansen, Johannes Blümel, Rainer Seitz, Albrecht Gröner, Johanna Strobel, Christian Drosten, Thomas Montag-Lessing, Reinhard Burger, and Georg Pauli
- Subjects
Human cytomegalovirus ,business.industry ,Immunology ,MEDLINE ,Immunology and Allergy ,Medicine ,Hematology ,Bioinformatics ,business ,medicine.disease ,Clinical Information · Klinische Information - Published
- 2010
35. How Up to Date Was This Information?
- Author
-
Lutz Gürtler
- Subjects
Arenavirus ,biology ,business.industry ,Transmission (medicine) ,viruses ,virus diseases ,General Medicine ,medicine.disease_cause ,biology.organism_classification ,Lymphocytic choriomeningitis ,medicine.disease ,Virology ,Transplantation ,Flavivirus ,Pneumocystis carinii ,Immunology ,medicine ,Pneumocystis jirovecii ,business ,Coronavirus - Abstract
I have several criticisms relating to the published box. No mention is made of its source. In the United States, West Nile virus occurs to an epidemiologically relevant degree in birds and humans; transmission to humans in Germany has not occurred thus far, according to all reports that are currently available. Further investigations in the Robert Koch-Institute have not provided any indication of the prevalence of this flavivirus in humans in Germany either. LCMV refers to the lymphochoriomeningitis virus, not the lymphocytic choriomeningitis virus, This arenavirus occurs in rodents in the US, especially in mice. In Germany, no infection has thus far occurred, even in children. SARS is the “severe acute respiratory syndrome” coronavirus, which was epidemiologically highly relevant in 2002 and 2003. A less pathogenic similar coronavirus caused a second small epidemic in China in 2004; since then, this zoonotic coronavirus has remained irrelevant for central Europe and the US. Pneumocystis is clinically important after transplantation. However, since 2004/05, this fungus, which occurs in human beings, has been renamed Pneumocystis jirovecii and not Pneumocystis carinii. An article that was published in 2009 should have included current terminology and meanings..
- Published
- 2010
- Full Text
- View/download PDF
36. Arboprotozoae
- Author
-
Lutz Gürtler
- Subjects
Immunology and Allergy ,Transfusion Medicine and Hemotherapy ,Hematology - Published
- 2009
37. Malaria
- Author
-
Lutz Gürtler
- Subjects
Immunology and Allergy ,Transfusion Medicine and Hemotherapy ,Hematology - Published
- 2009
38. Arbobacteria - Pathogens Transmittable by Arthropods
- Author
-
Lutz, Gürtler, Johannes, Blümel, Reinhard, Burger, Christian, Drosten, Albrecht, Gröner, Margarethe, Heiden, Walter, Hitzler, Bernd, Jansen, Horst, Klamm, Wolf-Dieter, Ludwig, Thomas, Montag-Lessing, Ruth, Offergeld, Georg, Pauli, Rainer, Seitz, Uwe, Schlenkrich, Volkmar, Schottstedt, and Hannelore, Willkommen
- Subjects
Clinical Information · Klinische Information - Published
- 2007
39. Influenza Virus
- Author
-
Johannes, Blümel, Reinhard, Burger, Christian, Drosten, Albrecht, Gröner, Lutz, Gürtler, Margarethe, Heiden, Martin, Hildebrandt, Bernd, Jansen, Horst, Klamm, Thomas, Montag-Lessing, Ruth, Offergeld, Georg, Pauli, Rainer, Seitz, Uwe, Schlenkrich, Volkmar, Schottstedt, Hannelore, Willkommen, and Carl-Heinz Wirsing, von König
- Subjects
Immunology and Allergy ,Transfusion Medicine and Hemotherapy ,Hematology ,Clinical Information · Klinische Information - Published
- 2007
40. Erratum zu: Nachweis einer Infektion mit Humanem Immundefizienzvirus (HIV): Serologisches Screening mit nachfolgender Bestätigungsdiagnostik durch Antikörper-basierte Testsysteme und/oder durch HIV-Nukleinsäure-Nachweis
- Author
-
Helmut Fickenscher, Marcus Panning, Martin Enders, Annemarie Berger, Holger F. Rabenau, Norbert Bannert, Lutz Gürtler, Claudia Kücherer, Klaus Korn, Rolf Kaiser, Micha Nübling, Oliver Donoso Mantke, Albert Heim, Martin Obermeier, Sigrid Nick, Daniela Huzly, Josef Eberle, Hans-Peter Grunert, and Heinz Zeichhardt
- Subjects
media_common.quotation_subject ,Public Health, Environmental and Occupational Health ,Art ,Humanities ,media_common - Abstract
In der Originalpublikation dieses Beitrags wurden die Autoren leider nicht innerhalb der Metadaten aufgefuhrt. Die Liste der Autoren lautet wie folgt: Holger F. Rabenau, Norbert Bannert, Annemarie Berger, Oliver Donoso Mantke, Josef Eberle, Martin Enders, Helmut Fickenscher, Hans-Peter Grunert, Lutz Gurtler, Albert Heim, Daniela Huzly, Rolf Kaiser, Klaus Korn, Sigrid Nick, Claudia Kucherer, Micha Nubling, Martin Obermeier, Marcus Panning, Heinz Zeichhardt.
- Published
- 2015
41. Construction and characterization of an HIV-1 group O infectious molecular clone and analysis of vpr- and nef-negative derivatives
- Author
-
Hans-Georg Kräusslich, Oliver T. Fackler, Lutz Gürtler, Ottmar Herchenröder, Denis M. Tebit, Lazare Kaptue, Leopold Zekeng, and Oliver T. Keppler
- Subjects
viruses ,Genes, vpr ,Molecular Sequence Data ,Reading frame ,Clone (cell biology) ,Gene Products, gag ,Gene Products, pol ,HIV Infections ,Biology ,medicine.disease_cause ,Virus Replication ,Virus ,Molecular clone ,Virology ,medicine ,Coding region ,Humans ,Primary isolate ,Cloning, Molecular ,Gene ,Cells, Cultured ,Phylogeny ,Mutation ,Virulence ,virus diseases ,Genes, nef ,Viral replication ,HIV-1 ,Gene Deletion - Abstract
In this report, we describe the construction and characterization of the first full-length infectious molecular clone from the Cameroonian HIV-1 group O primary isolate MVP8913. Virus obtained after transfection of the proviral clone pCMO2.3 replicated to levels comparable to its parental isolate in the human T-cell line PM-1, although replication was reduced by fivefold in peripheral blood mononuclear cells (PBMC) and was barely detectable in primary monocyte-derived macrophages (MDM). Phylogenetic analysis of the complete proviral sequence revealed a closer relationship to ANT70 than to MVP5180, the two prototypic group O primary isolates. All reading frames for structural and accessory genes were open except for vpr that contained an in-frame stop codon. In the nef gene, a mutation disrupting the functionally important myristoylation signal was observed. Repairing the defect in nef enhanced replication in PBMC and MDM, although repairing the vpr defect only affected replication in MDM, consistent with the known phenotypes of vpr and nef mutants in HIV-1 group M viruses. Repairing both vpr and nef showed an additive effect, but the resulting virus was still impaired compared to the parental isolate. This defect was overcome when the gag-pol coding region was exchanged for that from another O-type isolate giving rise to the proviral clone pCMO2.5. Virus obtained from pCMO2.5 replicated with similar kinetics as the parental O-type isolate in both PBMC and MDM, making this proviral clone a valuable tool for further studies on functional characteristics of HIV-1 group O viruses.
- Published
- 2004
42. HIV and Drug Resistance – Interpretation and Therapeutic Progress
- Author
-
Lutz Gürtler
- Subjects
medicine.medical_specialty ,business.industry ,Interpretation (philosophy) ,Human immunodeficiency virus (HIV) ,MEDLINE ,Drug resistance ,medicine.disease_cause ,Antiretroviral therapy ,Infectious Diseases ,Virology ,medicine ,Intensive care medicine ,business ,Introductory Journal Article - Published
- 2012
43. Anmerkungen zum HIV-Antigen Screening bei Blutspenden
- Author
-
G. Matthes, Lutz Gürtler, A. Poschmann, R. Gilcher, A.-M. Jullien, G. Holzberger, K. Baumgarten, P. Kühnl, D. Henrard, H. Hampl, and P. Chiewsilp
- Subjects
Immunology and Allergy ,Hematology - Published
- 1993
44. Detection of HIV-1 infection in dried blood spots from a 12-year-old ABO bedside test card
- Author
-
Erwin Strobel, Ch. Emminger, J. Eberle, Lutz Gürtler, and G. Mayer
- Subjects
medicine.medical_specialty ,Human immunodeficiency virus (HIV) ,Blood Donors ,medicine.disease_cause ,Pathology and Forensic Medicine ,ABO Blood-Group System ,Risk Factors ,ABO blood group system ,Internal medicine ,Bedside test ,Genetics ,medicine ,Humans ,Mass Screening ,Dried blood ,Acquired Immunodeficiency Syndrome ,Hematologic Tests ,Spots ,business.industry ,Public Health, Environmental and Occupational Health ,virus diseases ,Transfusion Reaction ,Hematology ,General Medicine ,Middle Aged ,Psychiatry and Mental health ,Blood Stains ,HIV-1 ,Female ,business - Abstract
We tested dried blood from an ABO bedside test card which had been stored at room temperature for 12 years, to prove that a patient with HIV-1 infection had been infected by blood transfusion.Immunoblots for HIV-1 antibodies and threefold PCRs with half-nested primers for the HIV-1 integrase gene were done with eluates from the dried blood spots.HIV-1 antibodies and HIV-1 DNA could be detected in the sample from one unit of blood, but not from the two other units or from the recipient before transfusion.Further studies should be done on the validity of stored dried blood as an alternative to the storage of frozen donor serum for several years for 'look-back' studies.
- Published
- 1999
45. The Impact of HIV Subtypes and Variants on the Stability of HIV Screening Assays
- Author
-
Lutz Gürtler
- Subjects
business.industry ,Immunology ,Immunology and Allergy ,Medicine ,HIV screening ,Hematology ,business ,Virology ,Hiv subtypes - Published
- 1998
46. Autorenverzeichnis Band 21, 1994/Author Index Vol. 21, 1994
- Author
-
K. Trenkel, D. Glück, T. Böhler, K. Knoblauch, G. Zilow, Bernhard Kubanek, M. Mohr, T. Zeiler, N. Schwella, B. Fölsch, Gerhard Lanzer, E. Rügheimer, Volker Kretschmer, A. Janecke, W. Weise, T. Dengler, A. Sputtek, G. Holzberger, Ch. Gabriel, S. Krug, E. Gossrau, K. Hempel, R. Langer, Lutz Gürtler, W. Gräßmann, M. Kirschfink, M. Grimm, M.M. Wilders-Truschnig, J. Sternberger, D. Roelcke, Walter Sibrowski, H.A. Henrich, R. Steigerwald, E. Pscheidl, R. Albrecht, G. Elbert, D. Huhn, Rainer Blasczyk, Robert Zimmermann, S. Reisch, and O. Linderkamp
- Subjects
Index (economics) ,Statistics ,Immunology and Allergy ,Hematology ,Mathematics - Published
- 1994
47. Reducing blood transfusion
- Author
-
Lutz Gürtler and Vipin Zamvar
- Subjects
Focus (computing) ,Blood transfusion ,business.industry ,medicine.medical_treatment ,General Engineering ,General Earth and Planetary Sciences ,Medicine ,General Medicine ,Medical emergency ,business ,medicine.disease ,General Environmental Science - Published
- 2002
48. MDS-Patienten profitieren anhaltend von der Behandlung mit r-HuEPO und G-CSF
- Author
-
U. Finsterer, H. Hampl, M.P. Busch, Markus Rehm, H. Brechtelsbauer, S.L. Stramer, M. Haller, U. Bothner, J. Barbara, Michael Georgieff, Lutz Gürtler, C. Akbulut, J. Löwer, N. Vogt, W.K. Roth, and G. Lerch
- Subjects
Immunology and Allergy ,Hematology - Published
- 1998
49. Impressum, Vol. 21, supplement 1, 1994
- Author
-
J. Eberle, J.U. Wieding, Walter Sibrowski, Lutz Gürtler, E. Bösenberg, B. Weber, G.-D. Burchard, C. Schneider, T.F. Schwarz, W. Jilg, H.W. Doerr, A. Bösenberg, J. Wüllenweber, Lutz G. Gürtler, L. Bader, J. Hilfenhaus, M. Roggendorf, H. Pollmann, M. Köhler, and M. Penner
- Subjects
Immunology and Allergy ,Hematology - Published
- 1994
50. Inhibition of HIV replication in cell culture by the specific aspartic protease inhibitor pepstatin A
- Author
-
Klaus Von Der Helm, Josef Eberle, Friedrich Deinhardt, and Lutz Gürtler
- Subjects
Pepstatin A ,HIV Antigens ,HIV Core Protein p24 ,Retroviridae Proteins ,Biophysics ,Biology ,Virus Replication ,Biochemistry ,Virus ,Cell Line ,chemistry.chemical_compound ,Antigen ,Structural Biology ,Endopeptidases ,Pepstatins ,HIV protease ,Genetics ,Aspartic Acid Endopeptidases ,Protease Inhibitors ,Molecular Biology ,Incubation ,chemistry.chemical_classification ,HIV ,virus diseases ,RNA-Directed DNA Polymerase ,Virus inhibition ,Cell Biology ,Virology ,Reverse transcriptase ,Enzyme ,chemistry ,Enzyme inhibitor ,Cell culture ,biology.protein ,Oligopeptides ,Pepstatin - Abstract
After incubation of H9 cells infected with human immunodeficiency virus (HIV) with pepstatin A at 10 −4 M for 2, 4, or 11 days, the culture medium contained significantly less HIV core antigen (p24) than controls without pepstatin A and no or only borderline activity of reverse transcriptase was detected. In addition, after pepstatin A treatment no infectious HIV at 2 or 4 days and only minimal amounts at 11 days were detectable in the culture medium.
- Published
- 1989
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.